RxDoctor Payments Data

Matthew Dairman, DPM

Foot & Ankle Surgery · Suffolk, VANPI 1144226853

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,638 of the $6,387 with a category attached, or 72.6%. It is spread thinly across 33 manufacturers, the largest accounting for just 18.6%. 2025 is the largest year on record at $2,096, 6.7 times the $314 reported in 2019.

$6,387in general payments, 2019–2025

Across 105 payments — averaging $60.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo USA, Inc.$1K
  • Stryker$971
  • Treace Medical Concepts, Inc.$925
  • Smith+Nephew$444
  • Bioventus LLC$270
  • KCI USA, Inc.$270
  • plus $2K from 27 others
$373,299in research payments, 2019–2025

Across 39 payments — averaging $9571.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endo Pharmaceuticals Inc.$241K
  • Ipsen Innovation$120K
  • Bristol Myers Squibb$9K
  • Integra Lifesciences Corporation$3K

What the payments were for

  • Travel & lodging$1,74827%
  • Food & beverage$4,63873%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,387 in reported general payments places this provider in the 65th percentile of 260 foot & ankle surgery providers in Virginia.

See all foot & ankle surgery providers in Virginia

Medicare billing

Part B allowed, 2024
$238,113
Medicare patients
617
Services billed
3,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CiclopiroxCiclopirox Olamine68$1,104
Terbinafine Hcl28$575
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip19$341
Meloxicam92$251
Cefdinir17$223
Methylprednisolone17$125

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Suffolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →